Adulterated kratom: what's actually in "enhanced" products
When you buy a product labeled "kratom extract," "enhanced kratom," or "full spectrum kratom," there is no regulatory requirement that the label accurately reflects what is inside. No federal agency must certify the potency, verify the ingredients, or test for contaminants before the product reaches the shelf. Whatever the manufacturer chose to put in, and whatever ended up there through poor manufacturing practices, goes directly to the consumer.
The documented findings from FDA testing, seized product analyses, and published research show that commercial kratom products can contain considerably more than the plant. Some contain concentrated or synthesized 7-OH that makes them opioid-strength. Some have had undeclared pharmaceutical drugs found inside. Some have tested for heavy metals at levels unsafe for chronic consumption. And one multi-state Salmonella outbreak was directly traced to kratom products.
"It's just a plant" is marketing. The actual product may be something else entirely.
At a glance: what can be in a kratom product
Key Takeaways
- Commercial kratom products are unregulated. No federal agency certifies their potency, ingredients, or safety before they reach consumers.
- "Enhanced" often means synthetically strengthened. Concentrated or synthesized 7-OH products can be dramatically more potent than anything the plant produces naturally.
- The FDA has documented undeclared drugs in seized kratom supplements, including opioids and benzodiazepines not listed on the label.
- In 2018, FDA testing of 26 commercial kratom products found lead and/or nickel in all 26 at levels the agency described as "not safe for human consumption" with chronic use.
- A 2018 Salmonella outbreak linked to kratom products sickened 199 people across 41 states. The FDA issued its first-ever mandatory food recall order in response.
- The core safety problem is that consumers cannot know what they are actually taking, which makes assessing dose, risk, or effect impossible.
Why kratom is a regulatory black box
Kratom occupies an unusual position in the U.S. market. It is not FDA-approved as a drug. The FDA has stated it cannot be lawfully marketed as a dietary supplement because its alkaloids are pharmacologically active and were not on the market as supplements before they were investigated as drugs. It is not a controlled substance under the Controlled Substances Act, though that is changing for concentrated 7-OH. It is sold openly, but without the requirements that apply to either drugs or legitimate dietary supplements.
The consequence of this gap is that no one is required to:
- Verify that the product contains what the label says it contains
- Test for contaminants before sale
- Standardize manufacturing conditions
- Report adverse events to any federal database
- Pull a product from the market unless the FDA can demonstrate it poses a safety risk through its own enforcement action
The FDA's regulatory toolkit for kratom is largely reactive rather than preventive. By the time action is taken on a specific product or company, that product has already been on shelves.
"Enhanced" kratom: what it actually means
The terms "enhanced kratom," "extract," "full spectrum," "ultra," and similar labels on commercial products do not have standardized definitions. In practice, they often describe kratom products that have been processed to increase their alkaloid concentration, particularly 7-OH.
In natural kratom leaf, 7-OH is present at trace concentrations of roughly 0.003% to 0.04% by dry weight. Commercial "enhanced" products can contain 7-OH at many times these levels. A peer-reviewed study published via PubMed found commercial products labeled as "kratom extract" containing 7-OH at 22 to 75 milligrams per gram, concentrations the researchers concluded were "achievable only by synthetic means."
One industry analysis cited products where 7-OH concentration was 500% or more above what occurs naturally in the leaf. At these concentrations, the product's pharmacological profile is closer to a pharmaceutical opioid than to a botanical.
Beyond 7-OH concentration, newer synthetic compounds that do not occur in the kratom plant at all have been found in products marketed as kratom extracts:
These are not botanical kratom products. They are laboratory-synthesized opioids sold in packaging that says "kratom." The DEA's July 2026 notices of intent to temporarily schedule all three reflect the same conclusion.
Undeclared drugs in kratom products
The FDA has documented seizures of kratom supplements that contained undeclared pharmaceutical drugs not listed on the label, including opioids and benzodiazepines. The FDA's "FDA and Kratom" page lists "FDA Announces Seizure of Adulterated Dietary Supplements Containing Kratom" among its enforcement actions, and the agency has issued warning letters and conducted import alerts targeting kratom products containing undeclared substances.
A person buying what they believe is a botanical kratom product may unknowingly be consuming pharmaceutical opioids or benzodiazepines at unknown concentrations, with no information on dosing, interactions, or contraindications.
Heavy metals: what the FDA found in 26 products
In response to the 2018 Salmonella outbreak linked to kratom, FDA field scientists collected and tested 26 separate commercial kratom products. The findings were published by FDA Commissioner Scott Gottlieb in a November 27, 2018 statement:
- All 26 products tested positive for lead and/or nickel
- Levels were described as "not safe for human consumption" with chronic use
- Commissioner Gottlieb stated: "some of these products included levels that, with chronic use, could cause some people to suffer from heavy metal poisoning"
- The FDA noted concern that other kratom products on the market may also contain heavy metals
An FDA spokesperson confirmed all 26 products contained lead and/or nickel. The agency was clear that a single dose was unlikely to cause acute poisoning, but that the concern was chronic exposure at the levels found.
Heavy metal poisoning from chronic exposure can cause neurological damage, kidney problems, cardiovascular effects, and gastrointestinal symptoms including abdominal pain, nausea, and diarrhea. People who have used kratom products regularly over months or years may have had sustained heavy metal exposure without knowing it.
Salmonella: the 2018 multistate outbreak
Kratom products were linked to a multistate Salmonella outbreak that began in late 2017 and was formally investigated by the FDA and CDC starting in early 2018. By the time the outbreak concluded:
The Salmonella strain (I 4,[5],12:b:-) was traced through the CDC's PulseNet system to kratom powder. The FDA noted that the contamination reflected the uncontrolled manufacturing conditions under which many kratom products are produced.
This was not a theoretical risk. It was a documented public health event affecting nearly 200 people across most of the United States, resulting from the absence of manufacturing standards for an unregulated botanical supplement.
Why this makes every batch a gamble
The accumulated picture from documented findings is not hypothetical:
- Potency varies dramatically and unpredictably between products and batches
- Products labeled as botanical kratom can contain synthetic opioids not disclosed on the label
- Pharmaceutical drugs have been found in products sold as supplements
- Every product tested in one FDA sampling round contained heavy metals
- Bacterial contamination from inadequate manufacturing led to a multistate outbreak
For a person using kratom, this means they cannot reliably know the potency, the alkaloid profile, or the contaminant load of what they are taking. This is why "there is no safe dose" language around kratom and 7-OH products is accurate: the dose is itself unknown even to the person consuming it.
This black-box quality also matters for anyone trying to assess their own dependence. When the product's actual content is uncertain, it is impossible to gauge what the body has adapted to or what stopping it will produce.
Frequently Asked Questions
What is adulterated kratom?
Adulterated kratom refers to kratom products that contain undisclosed substances beyond the plant's natural alkaloids. The FDA has documented seizures of kratom supplements containing undeclared opioids and benzodiazepines. Some products marketed as kratom extract contain concentrated or synthesized 7-OH or fully synthetic alkaloids at levels not disclosed on the label. Adulteration is possible precisely because kratom products are not subject to the manufacturing and testing requirements that apply to FDA-approved drugs.
What is enhanced kratom?
"Enhanced kratom" is a marketing term applied to kratom products that have been processed to increase their alkaloid concentration, typically 7-OH. The enhancement is not standardized. Products can range from moderately stronger-than-leaf to near-pure synthesized 7-OH. Because the term has no regulatory definition, a product labeled "enhanced kratom" tells you nothing specific about what is inside or how potent it is.
Did the FDA find heavy metals in kratom?
Yes. In 2018, FDA scientists tested 26 commercial kratom products and found lead and/or nickel in all 26 at levels described as "not safe for human consumption" with chronic use. FDA Commissioner Gottlieb stated that some products contained levels that "could cause some people to suffer from heavy metal poisoning" with chronic exposure, and expressed concern that other untested products may also contain heavy metals.
Was there a Salmonella outbreak from kratom?
Yes. A multistate Salmonella outbreak linked to kratom products sickened 199 people across 41 states in 2017 to 2018. Approximately 38% of confirmed cases required hospitalization. The FDA encouraged voluntary recalls and, when one company refused to comply, issued a mandatory recall order, described as the first-ever mandatory food recall in FDA history. No confirmed deaths were attributed to the outbreak.
How do I know what is in the kratom I am using?
In the absence of independent third-party testing with results you can verify, you largely cannot know. The product's label may not accurately reflect its actual content, and no federal testing requirement ensures accuracy. Some brands publish certificates of analysis from third-party labs; even those have limitations in what they test for. The fundamental problem is the absence of regulatory requirements that would make accurate labeling and contamination testing mandatory.
Sources
- U.S. Food and Drug Administration. Statement by FDA Commissioner Scott Gottlieb, MD, on risk of heavy metals, including nickel and lead, found in some kratom products. FDA; November 27, 2018. https://www.prnewswire.com/news-releases/statement-by-fda-commissioner-scott-gottlieb-md-on-risk-of-heavy-metals-including-nickel-and-lead-found-in-some-kratom-products-300756097.html
- U.S. Food and Drug Administration. FDA and Kratom. FDA; updated February 2026. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
- U.S. Food and Drug Administration. FDA Investigates Multistate Outbreak of Salmonella Infections Linked to Products Reported to Contain Kratom. FDA; February 2018. https://www.fda.gov/food/hfp-constituent-updates/fda-investigates-multistate-outbreak-salmonella-infections-linked-products-reported-contain-kratom
- Drug Enforcement Administration. Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I. Federal Register. Published July 6, 2026. Document No. 2026-13580. https://www.federalregister.gov/documents/2026/07/06/2026-13580/schedules-of-controlled-substance-temporary-placement-of-7-hydroxymitragynine-above-a-specified
- Drug Enforcement Administration. Schedules of Controlled Substance: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I. Federal Register. Published July 6, 2026. Document No. 2026-13581. https://www.federalregister.gov/documents/2026/07/06/2026-13581/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindoxyl-mgm-15-and
- Brown J, et al. Elevated 7-Hydroxymitragynine Levels Found in Products Misbranded as Kratom. Journal of Analytical Toxicology. 2025. PMID: 41065466. https://pubmed.ncbi.nlm.nih.gov/41065466/
- U.S. Food and Drug Administration. 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat. FDA; July 2025. https://www.fda.gov/files/drugs/published/7-hydroxymitragynin_7-oh_an_assessment_of_the_scientific_data_and_toxicological_concerns_around_an_emerging_opioid_threat.pdf
- Centers for Disease Control and Prevention. Multistate Outbreak of Salmonella I 4,[5],12:b:- Infections Linked to Kratom. CDC Investigation Notice. 2018. https://www.cdc.gov/salmonella/kratom-02-18/index.html
- Alsbrook S, Pro G, Koturbash I. From kratom to 7-hydroxymitragynine: evolution of a natural remedy into a public-health threat. Pharmaceutical Biology. 2025;63:896-911. doi:10.1080/13880209.2025.2590311.
- National Institute on Drug Abuse. Kratom. NIDA. Updated June 2025. https://nida.nih.gov/research-topics/kratom